INFOGRAPHIC: 2-year efficacy, durability and safety of intravitreal faricimab with treat-and-extend dosing up to 16 weeks in diabetic macular oedema (pooled results from YOSEMITE and RHINE)
Eye (Lond)
.
2024 Jul 29.
doi: 10.1038/s41433-024-03249-0.
Online ahead of print.
Authors
Naomi Wijesingha
1
2
,
Kara Gibson
3
,
Jeffrey R Willis
4
,
Sobha Sivaprasad
5
6
Affiliations
1
UCL Institute of Ophthalmology, London, UK.
2
Moorfields Eye Hospital NHS Foundation Trust, London, UK.
3
Roche Products Ltd., Welwyn Garden City, UK.
4
Genentech Inc., South San Francisco, CA, USA.
5
UCL Institute of Ophthalmology, London, UK. sobha.sivaprasad@nhs.net.
6
Moorfields Eye Hospital NHS Foundation Trust, London, UK. sobha.sivaprasad@nhs.net.
PMID:
39075261
DOI:
10.1038/s41433-024-03249-0
No abstract available